ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced receipt of U.S. Food and Drug Administration (FDA) and European CE Mark approvals of its newest pacemaker family, and the first implants of the devices. The Zephyr™ pacemaker is designed to save valuable clinic time by automatically performing all standard follow-up testing before the patient arrives in the clinic. Zephyr also is the first pacemaker that can, in about 90 seconds, tell physicians which device timing settings are optimal for each patient’s needs.
